These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23786523)

  • 1. A central role for inducible heat-shock protein 70 in autoimmune vitiligo.
    Mosenson JA; Eby JM; Hernandez C; Le Poole IC
    Exp Dermatol; 2013 Sep; 22(9):566-9. PubMed ID: 23786523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
    Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
    Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo.
    Denman CJ; McCracken J; Hariharan V; Klarquist J; Oyarbide-Valencia K; Guevara-Patiño JA; Le Poole IC
    J Invest Dermatol; 2008 Aug; 128(8):2041-8. PubMed ID: 18337834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP70i is a critical component of the immune response leading to vitiligo.
    Mosenson JA; Zloza A; Klarquist J; Barfuss AJ; Guevara-Patino JA; Poole IC
    Pigment Cell Melanoma Res; 2012 Jan; 25(1):88-98. PubMed ID: 21978301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress.
    Mosenson JA; Flood K; Klarquist J; Eby JM; Koshoffer A; Boissy RE; Overbeck A; Tung RC; Le Poole IC
    Pigment Cell Melanoma Res; 2014 Mar; 27(2):209-20. PubMed ID: 24354861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.
    Kroll TM; Bommiasamy H; Boissy RE; Hernandez C; Nickoloff BJ; Mestril R; Caroline Le Poole I
    J Invest Dermatol; 2005 Apr; 124(4):798-806. PubMed ID: 15816839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP70i
    Henning SW; Fernandez MF; Mahon JP; Duff R; Azarafrooz F; Guevara-Patiño JA; Rademaker AW; Salzman AL; Le Poole IC
    J Invest Dermatol; 2018 Dec; 138(12):2531-2539. PubMed ID: 30031029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
    Overwijk WW; Restifo NP
    Crit Rev Immunol; 2000; 20(6):433-50. PubMed ID: 11396680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma and Vitiligo: In Good Company.
    Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting iHSP 70 in vitiligo: a critical step for cure?
    Taïeb A; Seneschal J
    Exp Dermatol; 2013 Sep; 22(9):570-1. PubMed ID: 23947669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular basis of depigmentation in vitiligo patients.
    Delmas V; Larue L
    Exp Dermatol; 2019 Jun; 28(6):662-666. PubMed ID: 30536790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune aspects of vitiligo.
    Kemp EH; Waterman EA; Weetman AP
    Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP70i
    Jaishankar D; Cosgrove C; Ramesh P; Mahon J; Shivde R; Dellacecca ER; Yang SF; Mosenson J; Guevara-Patiño JA; Le Poole IC
    Cell Stress Chaperones; 2021 Sep; 26(5):845-857. PubMed ID: 34542825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to normal human melanocytes in vitiligo.
    Naughton GK; Eisinger M; Bystryn JC
    J Exp Med; 1983 Jul; 158(1):246-51. PubMed ID: 6345714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff.
    Boissy RE; Spritz RA
    Exp Dermatol; 2009 Jul; 18(7):583-5. PubMed ID: 19320739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for an autoimmune pathogenesis of vitiligo.
    Ongenae K; Van Geel N; Naeyaert JM
    Pigment Cell Res; 2003 Apr; 16(2):90-100. PubMed ID: 12622785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity?
    Xie H; Zhou F; Liu L; Zhu G; Li Q; Li C; Gao T
    J Dermatol Sci; 2016 Jan; 81(1):3-9. PubMed ID: 26387449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo: current medical and scientific understanding.
    Boissy RE; Nordlund JJ
    G Ital Dermatol Venereol; 2011 Feb; 146(1):69-75. PubMed ID: 21317859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
    Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
    Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.